Table 5. Selected clinical trials in... | American Society of Hematology

Table 5.

Selected clinical trials in advanced-stage Hodgkin lymphoma using novel agents

Trial	N	Clinical disease features	Median age, y	Therapy received/arms of treatment	Median follow-up, y	Response	PFS	OS
ECHELON 1³¹	1334	Stage III or IV	36	1. ABVD × 6 2. BV-AVD × 6	5.1		BV-AVD 5-year PFS 82.2% ABVD 5-year PFS 75.3%
CHECKMATE 205³⁴	51	Stage III, IV, or IIB with unfavorable risk factors	37	Nivo × 4 → nivo + AVD × 6	0.93	84% ORR, 67% CR	9-month PFS 92%	9-month OS 98%
Sequential Pembro and AVD²²	30	Stage I/II unfavorable only, stage III/IV	29	Pembro × 3 → AVD × 4-6 (4 cycles for early stage, 6 cycles for advanced stage or early-stage bulky)	1.9	CMR after pembro 37%, CMR after AVD 100%, EOT CMR 100%	Median PFS not reached, 2-year PFS 100%	Median OS not reached, 2-year OS 100%
Pembro + AVD²³	30	Stages I, II, III, IV	32	Pembro + AVD (2-6 cycles)	0.86	68% PET2–, 78% EOT PET–	1-year PFS 96%	1-year OS 100%

Trial	N	Clinical disease features	Median age, y	Therapy received/arms of treatment	Median follow-up, y	Response	PFS	OS
ECHELON 1³¹	1334	Stage III or IV	36	1. ABVD × 6 2. BV-AVD × 6	5.1		BV-AVD 5-year PFS 82.2% ABVD 5-year PFS 75.3%
CHECKMATE 205³⁴	51	Stage III, IV, or IIB with unfavorable risk factors	37	Nivo × 4 → nivo + AVD × 6	0.93	84% ORR, 67% CR	9-month PFS 92%	9-month OS 98%
Sequential Pembro and AVD²²	30	Stage I/II unfavorable only, stage III/IV	29	Pembro × 3 → AVD × 4-6 (4 cycles for early stage, 6 cycles for advanced stage or early-stage bulky)	1.9	CMR after pembro 37%, CMR after AVD 100%, EOT CMR 100%	Median PFS not reached, 2-year PFS 100%	Median OS not reached, 2-year OS 100%
Pembro + AVD²³	30	Stages I, II, III, IV	32	Pembro + AVD (2-6 cycles)	0.86	68% PET2–, 78% EOT PET–	1-year PFS 96%	1-year OS 100%

CMR, complete metabolic response.